Eli Lilly (LLY -1.2%) receives a blow in its attempts to overcome its patent expirations, saying...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly (LLY -1.2%) receives a blow in its attempts to overcome its patent expirations, saying its pomaglumetad methionil treatment for an acute exacerbation of schizophrenia missed the primary endpoint in a study. The company will await the results of two more trials before deciding its next steps.